Are Peptides Legal in Vermont? (2026)

By the Peptide Bureau Research Team Regulation Reviewed by the Peptide Bureau Research Team on 28 September 2026

Not legal advice. This page summarises public statutes, board statements and enforcement records for Vermont as of 28 September 2026, for general information. It is not a legal opinion. Laws change; check the linked sources or a licensed Vermont attorney before relying on anything here. Compounds are discussed in a research context only.

Short answer. There is no Vermont statute that bans buying or possessing research peptides as a category. Federal law does the regulating: selling an unapproved peptide for human use is a federal violation by the seller, and human growth hormone has its own federal statute. The Bureau found no peptide that Vermont has scheduled or banned on its own. Vermont's licensing boards have also spoken to peptide prescribing by clinics and medspas, which is where state-level risk actually sits (details below). Verified against the sources listed at the bottom on 28 September 2026. Not legal advice.

Vermont at a glance

State controlled-substances law: 18 V.S.A. chapter 84, Possession and Control of Regulated Drugs (18 V.S.A. § 4201 et seq.); specific substances designated by the Department of Health's Regulated Drug Rule under § 4202 (legislature.vermont.gov)
Human growth hormone under state law: Not separately scheduled; the federal statute 21 U.S.C. § 333(e) applies (18 V.S.A. § 4201; Vermont Regulated Drug Rule) (healthvermont.gov)
Research peptides scheduled by the state: None found
Board of Pharmacy on compounded GLP-1s: No statement located
Medical board on peptide prescribing: A joint statement from the Office of Professional Regulation and the Boards of Medical Practice, Nursing, Osteopathic Medicine and Pharmacy (approved 5 June 2024) says Vermont has no laws specific to IV therapy clinics and medical spas, that prescribing or administering drugs is the practice of medicine, that only MDs, DOs, PAs, APRNs and endorsed NDs may prescribe, that a valid prescription needs a practitioner-patient relationship, evaluation, diagnosis and documentation, that standing orders from a medical director are not valid prescriptions, and that compounding can never take place under a standing order because a compounding prescription must name an individual patient. Weight loss is named as a marketed medspa use. It does not mention peptides by name (2024-06-05) (healthvermont.gov)
GLP-1 by telehealth: 18 V.S.A. § 9361 holds telemedicine treatment and prescribing to the same standard as in-person care and allows treatment after an appropriate examination in person, by telemedicine or by transmitted diagnostic equipment; there is no in-person examination prerequisite. Out-of-state prescribers use the Office of Professional Regulation's telehealth registration, which proposed rules would cap at a small number of Vermont patients per period. GLP-1 pens are prescribable by telehealth on that basis. (legislature.vermont.gov)
State-level enforcement, 2023 to 2026: 1 action found
Last verified: 28 September 2026, confidence medium

The federal rules that apply in Vermont, as everywhere

Federal law is the same in every state, and it is where almost all of the legal weight sits. Under the Federal Food, Drug, and Cosmetic Act a product intended to treat a condition or change how the body works is a drug, and an unapproved new drug cannot be introduced into interstate commerce. That rule binds the seller, not the buyer. The FDA's 2026 warning letters to research-peptide vendors say the same thing eleven times over: a "research use only" label does not help when the website, the bundled bacteriostatic water or a dosing calculator shows the product is meant for human use. The Bureau's enforcement tracker lists every letter, case and lawsuit with its source.

Three federal points matter for a reader in Vermont:

Human growth hormone is the exception. 21 U.S.C. § 333(e) makes it a federal offence to distribute or possess somatropin for any use not approved by the Secretary of HHS. That statute covers HGH itself, not the secretagogues (sermorelin, ipamorelin, CJC-1295) that prompt the body's own release.
Compounding is a separate track. A licensed pharmacy may only compound from bulk substances on the FDA's 503A list. BPC-157, TB-500, MOTS-c, KPV, Semax and Epitalon were moved to Category 2 in September 2023, removed from it in April 2026, and recommended for the list by the FDA's advisory committee on 23 and 24 July 2026. No rule has followed as of September 2026, so they still cannot be legally compounded anywhere, including Vermont. The PCAC vote page has every tally.
GLP-1 compounding is closing, not opening. The FDA has declared the semaglutide and tirzepatide shortages over, proposed in April 2026 to keep both off the 503B bulks list, and sent batches of letters to telehealth sellers in March and June 2026. Vials sold as "GLP-1 S" or "GLP-3 R" for research are unapproved new drugs in the FDA's view wherever the buyer lives.

What Vermont law adds

Vermont's controlled-substances law (18 V.S.A. chapter 84, Possession and Control of Regulated Drugs (18 V.S.A. § 4201 et seq.); specific substances designated by the Department of Health's Regulated Drug Rule under § 4202) decides whether possessing a compound is a state offence. Peptides only become a state-law problem if they appear in those schedules or in a specific state ban. (legislature.vermont.gov)

The Bureau found no research peptide (BPC-157, TB-500, ipamorelin, sermorelin, semaglutide, tirzepatide, retatrutide or the others covered on this site) on Vermont's schedules or in a Vermont-specific ban as of September 2026. That is the position in most states.

Human growth hormone

Vermont does not use Schedules I to V. Its Regulated Drug Rule lists stimulant, depressant, narcotic and hallucinogenic drugs; the full text contains no growth hormone, somatropin, anabolic steroid or peptide entry. The 2019 version of the rule was the latest the Bureau could open. (18 V.S.A. § 4201; Vermont Regulated Drug Rule) (healthvermont.gov)

Compounded semaglutide and tirzepatide

No Vermont Board of Pharmacy statement specific to compounded GLP-1 drugs was located. Licensed Vermont pharmacies follow the federal 503A and 503B rules, under which the shortage exception for semaglutide and tirzepatide has ended.

Clinics, medspas and prescribers

2024-06-05. A joint statement from the Office of Professional Regulation and the Boards of Medical Practice, Nursing, Osteopathic Medicine and Pharmacy (approved 5 June 2024) says Vermont has no laws specific to IV therapy clinics and medical spas, that prescribing or administering drugs is the practice of medicine, that only MDs, DOs, PAs, APRNs and endorsed NDs may prescribe, that a valid prescription needs a practitioner-patient relationship, evaluation, diagnosis and documentation, that standing orders from a medical director are not valid prescriptions, and that compounding can never take place under a standing order because a compounding prescription must name an individual patient. Weight loss is named as a marketed medspa use. It does not mention peptides by name. (healthvermont.gov)

Buying, possessing and using research peptides in Vermont

HGH and research peptides are not regulated drugs under 18 V.S.A. § 4201 or the Regulated Drug Rule, so Vermont's chapter 84 possession offences do not apply and the federal rules govern. (legislature.vermont.gov)

Ordering from a vendor in another state. Almost every research-peptide order into Vermont is interstate commerce, which is exactly what the FDCA governs. The risk sits with the vendor: the FDA's letters name the seller, and Eli Lilly said in August 2026 it had referred more than 200 sellers to the FDA, the DOJ, state attorneys general and licensing boards. Connecticut's attorney general has already used state consumer-protection law against a "research grade" GLP-1 seller (2025), which is the template other states can copy. The Bureau's vendor scorecard notes which vendors publish batch testing; none of the scored vendors appears in the tracker as of September 2026.

GLP-1 drugs by prescription. 18 V.S.A. § 9361 holds telemedicine treatment and prescribing to the same standard as in-person care and allows treatment after an appropriate examination in person, by telemedicine or by transmitted diagnostic equipment; there is no in-person examination prerequisite. Out-of-state prescribers use the Office of Professional Regulation's telehealth registration, which proposed rules would cap at a small number of Vermont patients per period. GLP-1 pens are prescribable by telehealth on that basis. (legislature.vermont.gov) The branded pens are the only fully approved route; compounded versions are now on the wrong side of the FDA's shortage rules.

Sports and employment testing are not a Vermont law question. Growth hormone secretagogues and GHRH analogues are on the WADA Prohibited List everywhere; a standard workplace panel does not screen for peptides. The national legal guide covers both.

Not sure which of these you actually need?

Answer five questions about your goal, experience and budget and the Stack Builder shows you a matched research protocol on screen, with the compounds, cycle shape and vendor picks from the vendors we score.

Build your stack, 2 minutes

Enforcement in Vermont

2025-02-19. Vermont's attorney general joined the multistate letter urging the FDA to increase enforcement against counterfeit and illegally sold GLP-1 drugs. No Vermont-specific action involving peptides or GLP-1 sellers was found. (naag.org)

A warning letter, lawsuit or board complaint is an allegation by the body that issued it, not a court finding, unless the entry says otherwise.

Editor's note. The Board of Pharmacy's compounding rules could not be opened during this check, so no statement on compounded semaglutide is recorded; that is an absence of a located statement, not a finding that none exists.

Frequently asked questions

Is BPC-157 legal in Vermont?

Vermont has not scheduled BPC-157, so possessing it is not a Vermont offence. Federally it is an unapproved new drug: selling it for human use is a violation by the seller, and licensed pharmacies cannot compound it because it is not on the 503A bulks list, despite the advisory committee's July 2026 recommendation. Research vendors sell it under a research-use-only label, which the FDA's 2026 letters treat as no defence when the site shows human use.

Can I get semaglutide or tirzepatide by telehealth in Vermont?

18 V.S.A. § 9361 holds telemedicine treatment and prescribing to the same standard as in-person care and allows treatment after an appropriate examination in person, by telemedicine or by transmitted diagnostic equipment; there is no in-person examination prerequisite. Out-of-state prescribers use the Office of Professional Regulation's telehealth registration, which proposed rules would cap at a small number of Vermont patients per period. GLP-1 pens are prescribable by telehealth on that basis. Compounded versions are no longer covered by the FDA's shortage exception, and the FDA has proposed keeping semaglutide and tirzepatide off the 503B bulks list, so expect availability of compounded product to keep shrinking.

Is HGH legal in Vermont?

Only with a valid prescription for an approved use. Vermont does not schedule it separately, but federal law, 21 U.S.C. section 333(e), makes distribution or possession for any non-approved use a federal offence. Sermorelin, ipamorelin and CJC-1295 are not HGH and fall under the general unapproved-drug rules instead.

Sources

Every Vermont fact above was checked against the linked source on 28 September 2026. If a statute or board position has changed, email [email protected] with the link and the page will be corrected and dated.